ClinicalTrials.gg
Not yet recruitingNCT07551895HS_SW01Updated Apr 27, 2026

Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Primary Ovarian Insufficiency

A Phase 1/2 interventional study of HS_SW01 cells injection and HS_SW01 cells injection in Primary Ovarian Insufficiency (Poi), sponsored by Shenzhen Huishan Biotechnology Co., Ltd.. Not yet recruiting. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Shenzhen Huishan Biotechnology Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of human umbilical cord mesenchymal stem cell injection (HS_SW01 cells injection) in patients with Primary Ovarian Insufficiency (POI).

Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.

Read the detailed description

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of human umbilical cord mesenchymal stem cell injection (HS_SW01 cells injection) in patients with Primary Ovarian Insufficiency (POI).

Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.

This trial consists of a Phase I dose-escalation stage and a Phase II dose-expansion stage. Phase I is a randomized, double-blind, placebo-controlled design in which all participants receive background therapy plus a single intravenous infusion of HS_SW01 cells injection (1.0×10\^6 cells/kg, 2.0×10\^6 cells/kg, 3.0×10\^6 cells/kg) or placebo, with 4-7 participants per dose group. A "3+3" dose-escalation design is used to evaluate safety, tolerability, pharmacokinetics, and immunogenicity across the three dose groups. In Phase II, the optimal biological dose (OBD) identified from the Phase I escalation study will serve as the recommended Phase II dose (RP2D) to preliminarily assess efficacy while continuing safety monitoring, providing a basis for subsequent clinical trials.

Eligible participants are patients with POI aged ≥18 to \<40 years who meet all inclusion criteria and none of the exclusion criteria.

02

Conditions studied

  • Primary Ovarian Insufficiency (Poi)

Keywords

  • Primary Ovarian Insufficiency
  • MSC
03

In context

Primary Ovarian Insufficiency

181 studies on the registry are indexed under Primary Ovarian Insufficiency; 48 are open to participants now.

This study's planned enrollment of 21 is below the median of 48 across 113 interventional studies indexed under Primary Ovarian Insufficiency.

Browse Primary Ovarian Insufficiency studies →

Lead sponsor

Shenzhen Huishan Biotechnology Co., Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form;
  2. Age ≥18 to \<40 years, with oligomenorrhea or amenorrhea >4 months;
  3. Serum baseline FSH >25 U/L (at least two measurements, interval >4 weeks);
  4. Have received stable standard treatment for POI, such as ≥3 months of standardized hormone replacement therapy (HRT) with stable hormone levels;
  5. No fertility requirement and adherence to strict .

Exclusion criteria

Exclusion Criteria:

  1. Individuals with childbearing plans or those who are pregnant.
  2. Genetic disorders, chromosomal abnormalities, or genetic defects known to cause premature ovarian insufficiency (POI).
  3. Endocrine disorders affecting ovarian function, including polycystic ovary syndrome, hyperprolactinemia, hyperandrogenism, diabetes mellitus, and abnormalities of thyroid or adrenal function.
  4. Presence of breast, uterine, or ovarian tumors; known or suspected sex hormone-dependent ; or any other benign or malignant tumors.
  5. Primary amenorrhea.
  6. Uterine malformations.
  7. Iatrogenic or drug-induced ovarian insufficiency.
  8. Uncontrolled acute or chronic gynecological inflammation (including endometritis, etc.).
  9. Bilateral endometrial thickness ≤8 mm after moderate-to-severe intrauterine adhesion surgery.
  10. Complicated with endometriosis.
  11. Severe functional impairment of major organs or coagulation disorders.
  12. Active venous or arterial thromboembolic disease within the past 6 months.
  13. Severe hepatic or renal insufficiency, etc.
  14. Vaccination with live or within 2 months prior to enrollment.
  15. Prior treatment with mesenchymal stem cells less than 3 months before enrollment.
  16. Uncontrolled hypertension (>150/100 mmHg).
  17. Any of the following conditions within 3 months prior to enrollment:

    1. Major trauma or major surgery (including joint surgery), or anticipated need for major surgery during the study period, which in the investigator's opinion poses unacceptable risk to the participant;
    2. Receipt of plasma exchange or extracorporeal photopheresis;
    3. Participation in any other interventional clinical trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Low dose group

    intravenous inject MSCs

    Drug: HS_SW01 cells injection

  • Experimental
    Medium dose group

    intravenous inject MSCs

    Drug: HS_SW01 cells injection

  • Experimental
    High dose group

    intravenous inject MSCs

    Drug: HS_SW01 cells injection

Interventions

  • DrugHS_SW01 cells injection

    A single dose of 1×10\^6 cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.

  • DrugHS_SW01 cells injection

    A single dose of 2×10\^6 cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.

  • DrugHS_SW01 cells injection

    A single dose of 3×10\^6 cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.

06

What researchers measure

Primary outcomes

  1. The incidence of DLT

    Incidence of dose-limiting toxicities (DLTs) within 28 days following study drug administration.

    Time frame: Within 28 Days

Secondary outcomes

  1. Changes of the Anti-Müllerian hormone (AMH) serum level from baseline.

    Evaluate the AMH serum level by blood sampling at baseline and at Week 4, Week 12 and Week 24 after administration to assess changes of the Anti-Müllerian hormone (AMH) serum level from baseline.

    Time frame: Baseline, Week 4, Week 12, Week 24

  2. Changes of the Follicle Stimulating Hormone (FSH) serum level from baseline.

    Evaluate the FSH serum level by blood sampling at baseline and at Week 4, Week 12 and Week 24 after administration to assess changes of the Follicle Stimulating Hormone (FSH) serum level from baseline.

    Time frame: Baseline, Week 4, Week 12, Week 24

  3. Changes of Luteinizing Hormone (LH) serum level from baseline.

    Evaluate the LH serum level by blood sampling at baseline and at Week 4, Week 12 and Week 24 after administration to assess changes of Luteinizing Hormone (LH) serum level from baseline.

    Time frame: Baseline, Week 4, Week 12, Week 24

  4. Changes of the Estradiol (E2) serum level from baseline.

    Evaluate the E2 serum level by blood sampling at baseline and at Week 4, Week 12 and Week 24 after administration to assess changes of the Estradiol (E2) serum level from baseline.

    Time frame: Baseline, Week 4, Week 12, Week 24

  5. Changes of the Antral Follicle Counting (AFC) from baseline.

    Evaluate the Antral Follicle Counting (AFC) by sonography at baseline and at Week 4, Week 12 and Week 24 after administration to assess Changes of the Antral Follicle Counting (AFC) from baseline .

    Time frame: Baseline, Week 4, Week 12, Week 24

  6. Changes of the Ovarian Volume (OV) from baseline.

    Evaluate the Ovarian Volume (OV) by sonography at baseline and at Week 4, Week 12 and Week 24 after administration to assess Changes of the Ovarian Volume (OV) from baseline.

    Time frame: Baseline, Week 4, Week 12, Week 24

  7. Changes of the menstrual function indicators from baseline.

    Menstrual function indicators will be recorded via patient diaries or visit questionnaires to evaluate the recovery of menstruation following treatment. The form includes the date of menstrual onset, duration of menstruation (in days), menstrual regularity (regular/irregular; regular defined as cycle fluctuation ≤7 days), and associated symptoms (dysmenorrhea/other, with descriptive notes).Menstrual blood loss will be assessed using the Pictorial Blood Loss Assessment Chart (PBAC), which records, for each menstrual cycle, the type and number of sanitary products used daily, the frequency of clots passed into the toilet, and the total menstrual blood loss (in mL). Menstrual function recovery is defined as meeting all of the following criteria: (1)At least two consecutive cycles of menstrual bleeding after treatment discontinuation;(2)Cycle length restored to 21-35 days;(3)Menstrual blood volume returned to pre-illness levels compared with the subject's own baseline.

    Time frame: Up to Week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2026
First posted
Apr 27, 2026
StartEst.
Apr 15, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07551895
Lead sponsor
Shenzhen Huishan Biotechnology Co., Ltd.
Collaborators
Southern Medical University, China
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
Apr 15, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion